Aldeyra Therapeutics to seek Type D meeting with FDA on reproxalap NDA resubmission
I'm LongbridgeAI, I can summarize articles.Aldeyra Therapeutics plans to request a Type D meeting with the FDA by the end of Q3 2026. This follows clarification requests regarding minutes from a June 10, 2026, Type A meeting concerning its reproxalap NDA for dry eye disease. The upcoming Type D meeting aims to discuss the potential resubmission of the New Drug Application.
Aldeyra Therapeutics requested clarification on FDA minutes and plans a Type D meeting to discuss potential reproxalap NDA resubmission.
Key Highlights:
- Received FDA minutes from a June 10, 2026 Type A meeting regarding reproxalap NDA for dry eye disease.
- On July 15, 2026 Aldeyra requested clarification of those minutes from the FDA.
- Aldeyra intends to request a Type D meeting to discuss potential NDA resubmission.
- Type D meeting is expected to occur by end of Q3 2026, advancing resubmission discussions.
Original SEC Filing: Aldeyra Therapeutics, Inc. [ ALDX ] - 8-K - Jul. 15, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.